Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00870701
Other study ID # 08SARC01
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 19, 2009
Est. completion date March 10, 2017

Study information

Verified date August 2018
Source Institut Claudius Regaud
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Soft tissue sarcomas represent less than 1% of malignant tumors in adults and sarcomas members represent 60% of them.

These rare tumors involve complex multidisciplinary care better in centers having expertise.

Loco-regional therapy strategies have evaluated over time for tumors of members leading to propose more often the combination of a large conservative tumor excision with radiotherapy. Results have been demonstrated equivalent to those of an amputation in terms of local control and survival.

The local recurrence rate for sarcomas of the members of any kind after surgery with or without radiotherapy in the literature varies from 10 to 30%.

The main objective is to achieve a low recurrence rate while maintaining the function. The question remains the possibility of an absence of irradiation in selected cases in a de-escalation therapy order.


Recruitment information / eligibility

Status Terminated
Enrollment 77
Est. completion date March 10, 2017
Est. primary completion date March 10, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Soft tissue sarcoma members histologically confirmed

- Tumor primitive complete excision with margins greater than or equal to 10 mm in the soft tissue in all directions during the initial surgery.

A sub-centimeter margin is authorized under an anatomic barrier (fascia, fascia, inter-osseous membrane, periosteum), if surgery is R0 a margin sub-centimeter depth is allowed for superficial tumors if the underlying fascia RESECTED is not invaded.

- Primitive tumors without breaking initial tumor and without tumor residue in the systematic recovery in case of incomplete initial excision margins or doubtful

- WHO less than or equal to 2

- Age greater than or equal to 18 years

- Review extension negative (normal chest CT)

- Information and monitoring possible

- Patient affiliated to social security

Exclusion Criteria:

- Previously treated local sarcoma relapse

- Visceral or lymph node metastases

- pre-operative treatment (chemotherapy or radiotherapy)

- PNET, alveolar rhabdomyosarcoma, Darrier-Ferrand sarcoma

- excision margins of less than 10 mm in one direction or doubtful or unspecified, except under an anatomic barrier (fascia, fascia, inter-osseous membrane, periosteum), if surgery is R0 and tumors if the superficial fascia underlying RESECTED is not invaded.

- Break-tumor during the initial surgery, or residual tumor at second surgery

- Chemotherapy

- Delay between surgery R0 margins greater than or equal to 1 cm (initial surgery or recovery) and the start of radiotherapy exceeding 8 weeks

- History of radiation on the Member

- History of cancer (except carcinoma in situ of the cervix and basal cell skin cancer or in complete remission for over 5 years)

- Pregnant Women

- Patients under guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiotherapy
50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
Other:
absence of radiotherapy
absence of radiotherapy

Locations

Country Name City State
France Institut de Cancérologie de l'Ouest - Centre Paul Papin Angers
France Institut Bergonié Bordeaux
France Centre François Baclesse Caen
France Centre Jean Perrin Clermont Ferrand
France Hopital Mondor Créteil
France Centre Oscar Lambret Lille
France Centre Léon Bérard Lyon
France CHU de la Timone Marseille
France Institut Paoli Calmette Marseille
France Institut du Cancer de Montpellier - Val d'Aurelle Montpellier
France Centre Alexis Vautrin Nancy
France Centre Antoine Lacassagne Nice
France Centre Henri Becquerel Rouen
France Institut de Cancérologie de l'Ouest - Centre René Gauducheau Saint Herblain (Nantes)
France Institut de Cancerologie de La Loire Saint-Priest en Jarez
France Centre Paul Strauss Strasbourg
France Institut Claudius Regaud Toulouse
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Institut Claudius Regaud

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of local control at 5 years after surgery compared with exclusive post-operative radiotherapy for soft tissue tumors of the members who have surgery with wide excision margins greater than or equal to 10 mm. 2021
Secondary Evaluation of the quality of life by questionnaire of quality of life QLCQ30 2021
Secondary Evaluation of acute and late complications 2009 to 2021
Secondary Overall Survival 2021